Skip to main content
main-content

Free registration

Medicine Matters was developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

23-04-2018 | Gout | News

Verinurad–febuxostat combination shows promise for the treatment of gout

Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Editorial Board member Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

06-04-2018 | Spondyloarthropathy | Feature | Article

At a glance: Trials of tofacitinib in spondyloarthritis

A quick-reference guide to the published and ongoing clinical trials of tofacitinib for the treatment of spondyloarthritis.

Latest from across the site

24-04-2018 | Spondyloarthropathy | News

Pain, comorbidity burden high in patients with spondyloarthritis

Results of two studies emphasize the important of taking pain and comorbidities into account when treating patients with spondyloarthritis.

Source:

BMC Rheumatology 2018; 2: 11
Clin Rheumatol 2018; Advance online publication

23-04-2018 | Gout | News

Verinurad–febuxostat combination shows promise for the treatment of gout

Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

Source:

RMD Open 2018; 4: e000647

20-04-2018 | Juvenile idiopathic arthritis | News

JIA recommendations define treat-to-target strategy

An international taskforce has developed consensus recommendations for treating juvenile idiopathic arthritis to target.

Source:

Ann Rheum Dis 2018; Advance online publication

19-04-2018 | Certolizumab pegol | News

‘Reassuring’ data on certolizumab pegol use during pregnancy

Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.

Source:

Arthritis Rheumatol 2018; Advance online publication

18-04-2018 | Axial spondyloarthritis | News

News in brief

Further evidence for sustained benefits of adalimumab in axSpA

Extension results from the ABILITY-1 trial support the long-term benefits of adalimumab for patients with nonradiographic axial spondyloarthritis.

17-04-2018 | Axial spondyloarthritis | News

High TNF inhibitor retention rate in SpA patients

Researchers have found that the long-term retention rate for a first tumor necrosis factor inhibitor is favorable in patients with spondyloarthritis.

Source:

J Rheumatol 2018; Advance online publication

Meet our Editorial Board

New Content Item Meet our Advisory Board

image credits